Sagimet Biosciences (SGMT) Projected to Post Quarterly Earnings on Wednesday

Sagimet Biosciences (NASDAQ:SGMT) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.79) per share for the quarter.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.23. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Price Performance

Shares of SGMT opened at $3.22 on Monday. The firm has a market capitalization of $98.77 million, a PE ratio of -1.83 and a beta of 2.32. Sagimet Biosciences has a 1-year low of $1.73 and a 1-year high of $7.38. The company’s fifty day moving average price is $3.06 and its 200-day moving average price is $4.14.

Institutional Investors Weigh In On Sagimet Biosciences

An institutional investor recently bought a new position in Sagimet Biosciences stock. NewEdge Advisors LLC bought a new stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 32,290 shares of the company’s stock, valued at approximately $105,000. NewEdge Advisors LLC owned 0.11% of Sagimet Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 87.86% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Sagimet Biosciences in a report on Tuesday, March 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.40.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.